Jazz Pharmaceuticals (STU:J7Z) LT-Debt-to-Total-Asset : 0.50 (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Jazz Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Jazz Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.50.

Jazz Pharmaceuticals's long-term debt to total assets ratio increased from Sep. 2023 (0.46) to Sep. 2024 (0.50). It may suggest that Jazz Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Jazz Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Jazz Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals LT-Debt-to-Total-Asset Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.30

0.50

0.53

0.45

Jazz Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.46	0.45	0.46	0.46	0.50

Jazz Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Jazz Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	4738.334	/	10447.71
	=	0.45

Jazz Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	5542.877	/	11042.4
	=	0.50

Jazz Pharmaceuticals (STU:J7Z) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Jazz Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (STU:J7Z) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

JAZZ:USA J7Z:Germany

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals Headlines

No Headlines